Titre : Épilepsies myocloniques

Épilepsies myocloniques : Questions médicales fréquentes

Termes MeSH sélectionnés :

Complement Activation
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Épilepsies myocloniques : Questions médicales les plus fréquentes", "headline": "Épilepsies myocloniques : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Épilepsies myocloniques : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-27", "dateModified": "2025-04-23", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Épilepsies myocloniques" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Syndromes épileptiques", "url": "https://questionsmedicales.fr/mesh/D000073376", "about": { "@type": "MedicalCondition", "name": "Syndromes épileptiques", "code": { "@type": "MedicalCode", "code": "D000073376", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C10.228.140.490.493" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Épilepsies myocloniques progressives", "alternateName": "Myoclonic Epilepsies, Progressive", "url": "https://questionsmedicales.fr/mesh/D020191", "about": { "@type": "MedicalCondition", "name": "Épilepsies myocloniques progressives", "code": { "@type": "MedicalCode", "code": "D020191", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C10.228.140.490.493.063.650" } } }, { "@type": "MedicalWebPage", "name": "Épilepsie myoclonique juvénile", "alternateName": "Myoclonic Epilepsy, Juvenile", "url": "https://questionsmedicales.fr/mesh/D020190", "about": { "@type": "MedicalCondition", "name": "Épilepsie myoclonique juvénile", "code": { "@type": "MedicalCode", "code": "D020190", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C10.228.140.490.493.063.670" } } } ], "about": { "@type": "MedicalCondition", "name": "Épilepsies myocloniques", "alternateName": "Epilepsies, Myoclonic", "code": { "@type": "MedicalCode", "code": "D004831", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Pasquale Striano", "url": "https://questionsmedicales.fr/author/Pasquale%20Striano", "affiliation": { "@type": "Organization", "name": "IRCCS Istituto \"Giannina Gaslini\", Genova, Italy; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genova, Italy." } }, { "@type": "Person", "name": "Marte Syvertsen", "url": "https://questionsmedicales.fr/author/Marte%20Syvertsen", "affiliation": { "@type": "Organization", "name": "Department of Neurology, Drammen Hospital, Vestre Viken Health Trust, Oslo, Norway." } }, { "@type": "Person", "name": "Deb K Pal", "url": "https://questionsmedicales.fr/author/Deb%20K%20Pal", "affiliation": { "@type": "Organization", "name": "Department of Basic & Clinical Neurosciences, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK." } }, { "@type": "Person", "name": "None None", "url": "https://questionsmedicales.fr/author/None%20None", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Jeanette Koht", "url": "https://questionsmedicales.fr/author/Jeanette%20Koht", "affiliation": { "@type": "Organization", "name": "Department of Neurology, Drammen Hospital, Vestre Viken Health Trust, Oslo, Norway." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Complement-Coagulation Cross-talk: Factor H-mediated regulation of the Complement Classical Pathway activation by fibrin clots.", "datePublished": "2024-06-12", "url": "https://questionsmedicales.fr/article/38933264", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2024.1368852" } }, { "@type": "ScholarlyArticle", "name": "Synthetic Oligodeoxynucleotide CpG Motifs Activate Human Complement through Their Backbone Structure and Induce Complement-Dependent Cytokine Release.", "datePublished": "2022-09-14", "url": "https://questionsmedicales.fr/article/36104112", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.4049/jimmunol.2101191" } }, { "@type": "ScholarlyArticle", "name": "Inter-Individual Variations: A Challenge for the Standardisation of Complement Activation Assays.", "datePublished": "2023-02-11", "url": "https://questionsmedicales.fr/article/36816333", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2147/IJN.S384184" } }, { "@type": "ScholarlyArticle", "name": "Modeling complement activation on human glomerular microvascular endothelial cells.", "datePublished": "2023-10-25", "url": "https://questionsmedicales.fr/article/37954621", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2023.1206409" } }, { "@type": "ScholarlyArticle", "name": "Complement C3 activation in the ICU: Disease and therapy as Bonnie and Clyde.", "datePublished": "2022-07-16", "url": "https://questionsmedicales.fr/article/35853795", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.smim.2022.101640" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies du système nerveux", "item": "https://questionsmedicales.fr/mesh/D009422" }, { "@type": "ListItem", "position": 3, "name": "Maladies du système nerveux central", "item": "https://questionsmedicales.fr/mesh/D002493" }, { "@type": "ListItem", "position": 4, "name": "Encéphalopathies", "item": "https://questionsmedicales.fr/mesh/D001927" }, { "@type": "ListItem", "position": 5, "name": "Épilepsie", "item": "https://questionsmedicales.fr/mesh/D004827" }, { "@type": "ListItem", "position": 6, "name": "Syndromes épileptiques", "item": "https://questionsmedicales.fr/mesh/D000073376" }, { "@type": "ListItem", "position": 7, "name": "Épilepsies myocloniques", "item": "https://questionsmedicales.fr/mesh/D004831" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Épilepsies myocloniques - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Épilepsies myocloniques", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-08", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Épilepsies myocloniques", "description": "Comment diagnostiquer une épilepsie myoclonique ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels signes cliniques indiquent une épilepsie myoclonique ?\nL'épilepsie myoclonique est-elle héréditaire ?\nQuel rôle joue l'EEG dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=Complement+Activation&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Épilepsies myocloniques", "description": "Quels sont les symptômes principaux ?\nLes myoclonies sont-elles douloureuses ?\nPeut-on avoir des crises sans myoclonies ?\nLes symptômes varient-ils d'une personne à l'autre ?\nLes crises peuvent-elles survenir la nuit ?", "url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=Complement+Activation&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Épilepsies myocloniques", "description": "Peut-on prévenir les crises myocloniques ?\nQuels déclencheurs sont à éviter ?\nL'éducation est-elle importante pour la prévention ?\nLe suivi médical est-il essentiel ?\nLes activités physiques sont-elles sûres ?", "url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=Complement+Activation&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Épilepsies myocloniques", "description": "Quels médicaments sont utilisés pour traiter ?\nY a-t-il des traitements non médicamenteux ?\nComment évaluer l'efficacité du traitement ?\nLes traitements sont-ils à vie ?\nQuels effets secondaires des médicaments ?", "url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=Complement+Activation&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Épilepsies myocloniques", "description": "Quelles complications peuvent survenir ?\nL'épilepsie myoclonique peut-elle affecter la vie quotidienne ?\nY a-t-il un risque accru de dépression ?\nLes crises peuvent-elles entraîner des accidents ?\nComment gérer les complications psychologiques ?", "url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=Complement+Activation&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Épilepsies myocloniques", "description": "Quels sont les facteurs de risque connus ?\nL'âge influence-t-il le risque d'épilepsie myoclonique ?\nLes troubles neurologiques augmentent-ils le risque ?\nLe stress est-il un facteur de risque ?\nLes infections cérébrales sont-elles un risque ?", "url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=Complement+Activation&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une épilepsie myoclonique ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'historique médical, l'examen neurologique et l'EEG." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "L'EEG, l'IRM cérébrale et des tests sanguins peuvent être utilisés." } }, { "@type": "Question", "name": "Quels signes cliniques indiquent une épilepsie myoclonique ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des secousses musculaires rapides, souvent sans perte de conscience, sont typiques." } }, { "@type": "Question", "name": "L'épilepsie myoclonique est-elle héréditaire ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Certaines formes peuvent être héréditaires, nécessitant une évaluation familiale." } }, { "@type": "Question", "name": "Quel rôle joue l'EEG dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'EEG aide à détecter les anomalies électriques typiques des épilepsies myocloniques." } }, { "@type": "Question", "name": "Quels sont les symptômes principaux ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des myoclonies, des crises généralisées et parfois des absences." } }, { "@type": "Question", "name": "Les myoclonies sont-elles douloureuses ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les myoclonies ne sont généralement pas douloureuses, mais peuvent être gênantes." } }, { "@type": "Question", "name": "Peut-on avoir des crises sans myoclonies ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines personnes peuvent avoir des crises généralisées sans myoclonies." } }, { "@type": "Question", "name": "Les symptômes varient-ils d'une personne à l'autre ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'intensité et la fréquence des symptômes peuvent varier considérablement." } }, { "@type": "Question", "name": "Les crises peuvent-elles survenir la nuit ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des crises myocloniques peuvent survenir pendant le sommeil." } }, { "@type": "Question", "name": "Peut-on prévenir les crises myocloniques ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par un traitement adéquat et l'évitement des déclencheurs." } }, { "@type": "Question", "name": "Quels déclencheurs sont à éviter ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Le stress, la fatigue, et la consommation d'alcool peuvent déclencher des crises." } }, { "@type": "Question", "name": "L'éducation est-elle importante pour la prévention ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'éducation sur la maladie aide les patients à mieux gérer leur condition." } }, { "@type": "Question", "name": "Le suivi médical est-il essentiel ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi régulier permet d'ajuster le traitement et de surveiller les symptômes." } }, { "@type": "Question", "name": "Les activités physiques sont-elles sûres ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Certaines activités peuvent être sûres, mais il faut éviter les sports à risque." } }, { "@type": "Question", "name": "Quels médicaments sont utilisés pour traiter ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les anticonvulsivants comme le valproate et le lamotrigine sont couramment prescrits." } }, { "@type": "Question", "name": "Y a-t-il des traitements non médicamenteux ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des approches comme la thérapie comportementale et la diététique peuvent aider." } }, { "@type": "Question", "name": "Comment évaluer l'efficacité du traitement ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité est évaluée par la réduction des crises et les effets secondaires." } }, { "@type": "Question", "name": "Les traitements sont-ils à vie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Souvent, le traitement est à long terme, mais certains peuvent réduire ou arrêter." } }, { "@type": "Question", "name": "Quels effets secondaires des médicaments ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent inclure fatigue, vertiges et troubles gastro-intestinaux." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des blessures dues aux crises et des troubles psychologiques." } }, { "@type": "Question", "name": "L'épilepsie myoclonique peut-elle affecter la vie quotidienne ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut impacter la vie sociale, professionnelle et la qualité de vie." } }, { "@type": "Question", "name": "Y a-t-il un risque accru de dépression ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes épileptiques ont un risque plus élevé de dépression et d'anxiété." } }, { "@type": "Question", "name": "Les crises peuvent-elles entraîner des accidents ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les crises peuvent provoquer des accidents, notamment lors de la conduite." } }, { "@type": "Question", "name": "Comment gérer les complications psychologiques ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Un soutien psychologique et des thérapies adaptées peuvent aider à gérer ces complications." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque connus ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux, les traumatismes crâniens et certaines infections sont des facteurs." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque d'épilepsie myoclonique ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'épilepsie myoclonique peut débuter à tout âge, mais souvent dans l'enfance ou l'adolescence." } }, { "@type": "Question", "name": "Les troubles neurologiques augmentent-ils le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, d'autres troubles neurologiques peuvent augmenter le risque d'épilepsie myoclonique." } }, { "@type": "Question", "name": "Le stress est-il un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut déclencher des crises chez les personnes prédisposées." } }, { "@type": "Question", "name": "Les infections cérébrales sont-elles un risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections, comme la méningite, peuvent augmenter le risque d'épilepsie." } } ] } ] }

Sources (10000 au total)

Synthetic Oligodeoxynucleotide CpG Motifs Activate Human Complement through Their Backbone Structure and Induce Complement-Dependent Cytokine Release.

Bacterial and mitochondrial DNA, sharing an evolutionary origin, act as danger-associated molecular patterns in infectious and sterile inflammation. They both contain immunomodulatory CpG motifs. Inte...

Inter-Individual Variations: A Challenge for the Standardisation of Complement Activation Assays.

The role of the human immune system in pathologic responses to chemicals including nanomaterials was identified as a gap in current hazard assessments. However, the complexity of the human immune syst... We treated commercially available pooled sera (PS) from healthy males, individual sera from healthy donors and from patients suffering from cancer, immunodeficiency and allergies with small molecules ... The level of complement activation in PS differed significantly from responses of individual donors (p < 0.01). Only seven out of 32 investigated sera from healthy donors responded similarly to the po... Our studies demonstrate that the use of pooled serum can lead to an over- or under-estimation of immunological response in particular for individuals with pre-existing pathologies. This is of high rel...

Modeling complement activation on human glomerular microvascular endothelial cells.

Atypical hemolytic uremic syndrome (aHUS) is a rare kidney disease caused by dysregulation of the complement alternative pathway. The complement dysregulation specifically leads to damage to the glome... Endothelial cells were incubated with human test sera and stained with an anti-C5b-9 antibody to visualize and quantify complement depositions on the cells with immunofluorescence microscopy.... First, we showed that zymosan-activated sera resulted in increased endothelial C5b-9 depositions compared to normal human serum (NHS). The levels of C5b-9 depositions were similar between conditionall... In conclusion, we demonstrate a robust and reliable model to adequately measure C5b-9-based complement deposition on human control and patient ciGMVECs. This model can be used to study the pathophysio...

DAMPS and complement activation in platelet concentrates that induce adverse reactions in patients.

Patients with severe thrombocytopenia due to bone marrow failure and after chemotherapy are still treated with platelet transfusions. Platelet concentrates (PC) are associated with a high incidence of... Single donor apheresis platelet concentrates (SDA PCs) were produced in a regional setting of the French Blood Establishment. After transfusion samples were collected from PC and possible AR in patien... A total of 56 PC were included in the study. 30 PC induced no AR, and 26 induced AR (Febrile non-hemolytic transfusion reaction n = 16; Atypical Allergic Transfusion Reactions n = 11; hemodynamic inst... In this study, we observed an association between HMGB1 and CAP and the incidence of AR. Furthermore, we demonstrated that both HMGB1 and complement activation were correlated to platelet activation....

Minimal role for the alternative pathway in complement activation by HIT immune complexes.

Anti-platelet factor 4 (PF4)/heparin immune complexes that cause heparin-induced thrombocytopenia (HIT) activate complement via the classical pathway. Previous studies have shown that the alternative ... These studies sought to examine the contributions of the alternative pathway to complement activation by HIT antibodies.... Using IgG monoclonal (KKO) and/or patient-derived HIT antibodies, we compared the effects of classical pathway (BBK32 and C1-esterase inhibitor [C1-INH]), alternative pathway (anti-factor B [fB] or fa... Classical pathway inhibitors BBK32 and C1-INH and the combined classical/alternative pathway inhibitor sCR1 prevented KKO/HIT immune complex-induced complement activation, including release of C3 and ... Collectively, these findings suggest the alternative pathway contributes little in support of complement activation by HIT immune complexes. Additional in vitro and in vivo studies are required to exa...